Welcome to LookChem.com Sign In|Join Free

CAS

  • or
(1R)-1-[3-N-(tert-butyloxycarbonyl)aminophenyl]-3-(3,4-dimethoxyphenyl)-1-propanyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-piperidinecarboxylate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

215168-85-7

Post Buying Request

215168-85-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • (1R)-1-[3-N-(tert-butyloxycarbonyl)aminophenyl]-3-(3,4-dimethoxyphenyl)-1-propanyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-piperidinecarboxylate

    Cas No: 215168-85-7

  • Need to discuss

  • No requirement

  • Adequate

  • Hubei Moxin Biotechnology Co., Ltd
  • Contact Supplier

215168-85-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 215168-85-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,5,1,6 and 8 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 215168-85:
(8*2)+(7*1)+(6*5)+(5*1)+(4*6)+(3*8)+(2*8)+(1*5)=127
127 % 10 = 7
So 215168-85-7 is a valid CAS Registry Number.

215168-85-7Relevant articles and documents

Targeted Covalent Inhibition of Plasmodium FK506 Binding Protein 35

Atack, Thomas C.,Raymond, Donald D.,Blomquist, Christa A.,Pasaje, Charisse Flerida,McCarren, Patrick R.,Moroco, Jamie,Befekadu, Henock B.,Robinson, Foxy P.,Pal, Debjani,Esherick, Lisl Y.,Ianari, Alessandra,Niles, Jacquin C.,Sellers, William R.

, p. 2131 - 2138 (2020/12/17)

FK506-binding protein 35, FKBP35, has been implicated as an essential malarial enzyme. Rapamycin and FK506 exhibit antiplasmodium activity in cultured parasites. However, due to the highly conserved nature of the binding pockets of FKBPs and the immunosuppressive properties of these drugs, there is a need for compounds that selectively inhibit FKBP35 and lack the undesired side effects. In contrast to human FKBPs, FKBP35 contains a cysteine, C106, adjacent to the rapamycin binding pocket, providing an opportunity to develop targeted covalent inhibitors of Plasmodium FKBP35. Here, we synthesize inhibitors of FKBP35, show that they directly bind FKBP35 in a model cellular setting, selectively covalently modify C106, and exhibit antiplasmodium activity in blood-stage cultured parasites.

Synthesis and activity of bivalent FKBP12 ligands for the regulated dimerization of proteins

Keenan, Terence,Yaeger, David R.,Courage, Nancy L.,Rollins, Carl T.,Pavone, Mary Ellen,Rivera, Victor M.,Yang, Wu,Guo, Tao,Amara, Jane F.,Clackson, Tim,Gilman, Michael,Holt, Dennis A.

, p. 1309 - 1335 (2007/10/03)

The total synthesis and in vitro activities of a series of chemical inducers of dimerization (CIDs) is described. The use of small-molecule CIDs to control the dimerization of engineered FKBP12-containing fusion proteins has been demonstrated to have broad utility in biological research as well as potential medical applications in gene and cell therapies. The facility and flexibility of preparation make this new class of wholly synthetic compounds exceptionally versatile tools for the study of intracellular signaling events mediated by protein-protein interactions or protein localization. While some congeners possess potency comparable to or better than the first generation natural product-derived CID, FK1012, structure-activity relationships are complex and underscore the need for application-specific compound optimizations. Copyright (C) 1998 Elsevier Science Ltd.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 215168-85-7